Detalles de la búsqueda
1.
Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial.
Lancet
; 399(10319): 36-49, 2022 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34883053
2.
Serum HCoV-spike specific antibodies do not protect against subsequent SARS-CoV-2 infection in children and adolescents.
iScience
; 26(12): 108500, 2023 Dec 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-38089581
3.
Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial.
Lancet Respir Med
; 10(11): 1049-1060, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-35690076
Resultados
1 -
3
de 3
1
Próxima >
>>